Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 896

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 896
---
 contrary, neither the Company, an Affiliate, the Board, the Committee nor any person acting on behalf of the Company, an Affiliate, the Board or the Committee shall be liable to any Grantee or to the estate or beneficiary of any Grantee or to any other holder of an Award under the Plan by reason of any acceleration of income or any additional tax (including any interest and penalties), asserted by reason of the failure of an Award to satisfy the requirements of Code §§ 422 or 409A, by reason of Code § 4999 or otherwise asserted with respect to the Award, provided, that this Section 16.13 shall not affect any of the rights or obligations set forth in an applicable agreement between the Grantee and the Company or an Affiliate. [Remainder of Page Intentionally Left Blank] Annex H-19 Annex I September 17, 2024 M&A Committee of the Board of Directors of Bellevue Life Sciences Acquisition Corp. We hereby consent to the inclusion of our opinion letter, dated September 17, 2024, to the M&A Committee and the Board of Directors of Bellevue Life Sciences Acquisition Corp. as Annex H to, and to the references to such opinion in, the proxy statement/prospectus of Bellevue Life Sciences Acquisition Corp., which proxy statement/prospectus forms a part of the Registration Statement on Form S-4 of Bellevue Life Sciences Acquisition Corp. By giving such consent, we do not thereby admit that we are experts with respect to any part of such Registration Statement within the meaning of the term “expert” as used in, or that we come within the category of persons whose consent is required under Section 7 of, the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder. Very truly yours, /s/ Myung Seok Chae Choloc Asset Investment Advisory Co., Ltd. Dear Sirs: Choloc Asset Investment Advisory Co., Ltd. (“ Choloc ”) has been mandated by the M&A committee of the Board of Directors (the “ M&A Committee ”) of Bellevue Life Sciences Acquisition Corp. (“ BLAC ”), to provide an independent opinion to the M&A committee in connection with the Aggregate Consideration to be paid to the stockholders of OSR Holdings Co., Ltd. (“ OSR ” or the “ Company ”) in the contemplated share exchange transaction between BLAC and the stockholders of OSR (the “ Transaction ” or the “